“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Gregory A. Demopulos net worth and biography

Gregory Demopulos Biography and Net Worth

CEO of Omeros

Dr. Demopulos founded our company and has served as our president, chief executive officer and chairman of the board of directors since June 1994. Prior to founding Omeros, Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training in hand and microvascular surgery at Duke University. Dr. Demopulos currently serves on the board of trustees of the Smead Funds Trust, an open-end mutual fund company registered under the Investment Company Act of 1940. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University.

What is Gregory A. Demopulos' net worth?: The estimated net worth of Gregory A. Demopulos is at least $1.35 million as of November 17th, 2023. Dr. Demopulos owns 123,945 shares of Omeros stock worth more than $1,352,240 as of November 23rd. This net worth estimate does not reflect any other assets that Dr. Demopulos may own. Additionally, Dr. Demopulos receives an annual salary of $5,970,000.00 as CEO at Omeros. Learn More about Gregory A. Demopulos' net worth.
How old is Gregory A. Demopulos?: Dr. Demopulos is currently 65 years old. There are 7 older executives and no younger executives at Omeros. Learn More on Gregory A. Demopulos' age.
What is Gregory A. Demopulos' salary?: As the CEO of Omeros Co., Dr. Demopulos earns $5,970,000.00 per year. Learn More on Gregory A. Demopulos' salary.
How do I contact Gregory A. Demopulos?: The corporate mailing address for Dr. Demopulos and other Omeros executives is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. Omeros can also be reached via phone at (206) 676-5000 and via email at [email protected]. Learn More on Gregory A. Demopulos' contact information.
Has Gregory A. Demopulos been buying or selling shares of Omeros?: Gregory A. Demopulos has not been actively trading shares of Omeros during the last ninety days. Most recently, on Friday, November 17th, Gregory A. Md Demopulos bought 15,000 shares of Omeros stock. The stock was acquired at an average cost of $1.68 per share, with a total value of $25,200.00. Following the completion of the transaction, the chief executive officer now directly owns 123,945 shares of the company's stock, valued at $208,227.60. Learn More on Gregory A. Demopulos' trading history.
Who are Omeros' active insiders?: Omeros' insider roster includes Gregory Demopulos (CEO), and Michael Jacobsen (CAO). Learn More on Omeros' active insiders.

Gregory A. Demopulos Insider Trading History at Omeros

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/17/2023	Buy	15,000	$1.68	$25,200.00	123,945
6/17/2021	Sell	36,857	$14.90	$549,169.30	2,063,842
6/15/2021	Sell	36,856	$15.02	$553,577.12	2,063,842
4/8/2021	Sell	72,613	$17.84	$1,295,415.92	2,064,393
12/7/2016	Sell	306,124	$10.66	$3,263,281.84	1,987,025
12/6/2016	Sell	102,040	$10.80	$1,102,032.00	1,987,025
12/5/2016	Sell	102,040	$10.71	$1,092,848.40	1,987,025
12/2/2016	Sell	306,120	$11.58	$3,544,869.60	1,801,381

Gregory A. Demopulos Buying and Selling Activity at Omeros

Omeros Company Overview

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Today's Range

Now: $10.91

$7.46

$10.99

50 Day Range

MA: $4.37

$3.77

$7.73

2 Week Range

Now: $10.91

$1.81

$10.99

Volume

4,065,853 shs

Average Volume

492,615 shs

Market Capitalization

$632.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

“Fed Proof” Your Bank Account with THESE 4 Simple Steps

From Weiss Ratings | Ad